Intellia Therapeutics, Inc. (NTLA) Financial Statements
Intellia Therapeutics, Inc. (NTLA) reported trailing twelve-month revenue of $59.5M (up 12.6% year on year) and net income of -$400.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$348.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NTLAIntellia Therapeutics, Inc.Follow NTLA — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.04 | 0.06 | 0.03 | 0.05 | 0.04 | 0.06 | 0.07 | 0.06 | |
| Gross profit | 0.03 | 0.04 | 0.06 | 0.03 | — | — | — | — | — | |
| Research & development | 0.09 | 0.11 | 0.15 | 0.23 | 0.42 | 0.44 | 0.47 | 0.39 | 0.35 | |
| Operating income | -0.09 | -0.11 | -0.14 | -0.27 | -0.46 | -0.52 | -0.53 | -0.44 | -0.42 | |
| Pre-tax income | -0.09 | -0.10 | -0.13 | -0.27 | -0.47 | -0.48 | -0.52 | -0.41 | -0.40 | |
| Income tax | — | — | — | — | — | — | — | 0.00 | — | |
| Net income | -0.09 | -0.47 | -0.13 | -0.27 | -0.47 | -0.48 | -0.52 | -0.41 | -0.40 | |
| Diluted EPS ($) | -1.98 | -2.11 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | -3.00 | |
| Diluted shares (bn) | — | — | — | — | 0.077 | 0.089 | 0.099 | 0.108 | — |
USD billions · SEC XBRL
Intellia Therapeutics, Inc. — questions
- What is Intellia Therapeutics, Inc.'s revenue?
- $59.5M over the twelve months to 2026-06-30, up 12.6% year on year, from its 10-Q and 10-K filings.
- What is Intellia Therapeutics, Inc.'s net income?
- -$400.0M over the twelve months to 2026-06-30.
- What is Intellia Therapeutics, Inc.'s free cash flow?
- -$348.7M over the twelve months to 2026-06-30.
- What are Intellia Therapeutics, Inc.'s diluted earnings per share?
- $-3.00 over the twelve months to 2026-06-30.
Every figure on this page comes from Intellia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.